Glaucoma Companies Aerie (Nasdaq:AERI), Glaukos (NYSE:GKOS), Q BioMed (OTCQB:QBIO), Inotek (Nasdaq:ITEK), NicOx SA (Paris: COX.PA) Approach a Devasting Disease with a Variety of Treatments
New York, NY; Pt, Roberts, WA - April 7, 2016- Investorideas.com, a digital global news source covering leading sectors including medical technology and biotech stocks releases the following report on Glaucoma and public companies currently involved in the treatment of the disease. Glaucoma is a group of eye diseases which result in damage to the eye’s optic nerve and left untreated will lead to vision loss and eventual blindness.
US Companies currently working on Glaucoma treatments include Q BioMed Inc, (QBIO), Aerie Pharmaceuticals (AERI), Glaukos Corporation (GKOS), Inotek (ITEK).
Internationally, NicOx SA (Paris: COX.PA) and Santen Pharmaceuticals Co. Ltd. (Tokyo:4536) are leading the way with research and development and treatment options for the disease.
Read this article in full at http://www.investorideas.com/news/2016/biotech/04071.asp
On March 28, Aerie Pharmaceuticals (NasdaqGM:AERI) issued a press release announcing the that dosing commenced of the first patients enrolled in Mercury 2, the Company’s second Phase 3 registration trial of Roclatan™(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
The same day, Glaukos Corporation (NYSE:GKOS) announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its iStent® Trabecular Micro-Bypass Stent for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients diagnosed with mild to moderate open-angle glaucoma who are currently treated with ocular hypotensive medication. The iStent is the first-ever ab interno Micro-Invasive Glaucoma Surgery (MIGS) device approved for use in Japan.
Q BioMed Inc, (OTCQB:QBIO) expanded on the company’s Corporate Update with a Q&A with Investorideas.com and a video interview with StockNewsNow was also released.
In both interviews, President Denis Corin included the Mannin Research Inc. license agreement and the glaucoma eye drop treatment being developed by Dr. Susan Quaggin. Mannin Research’s (Mannin) Glaucoma therapeutic is a first-in-class therapeutic designed to treat Primary Open-Angle Glaucoma. It is based on the research by Dr. Susan Quaggin, Director of the Feinberg Cardiovascular Research Institute and Chief of the Division of Nephrology and Hypertension at Northwestern University. The MAN-01 therapeutic is an important molecule in the context of new pharmaceuticals that can treat Glaucoma. Mannin’s therapeutic will address increased intraocular pressure in the eye by acting on a vessel in the eye called the Schlemm’s Canal, which is a main drainage path for the eye. Mannin is currently in the pre-clinical phase. Optimizing the molecule, the aim is to use it in the clinic in late 2017/early 2018.
Sources: http://finance.yahoo.com/news/stocknewsnow-com-publishes-snnlive-video-123000560.html and http://finance.yahoo.com/news/president-q-biomed-inc-expands-120000146.html
In early March, Inotech Pharmaceutical Corporation (NasdaqGM: ITEK) announced that it had strengthened the Patent Estate for its lead drug candidate Trabodenoson, an investigational agent currently in pivotal Phase 3 clinical trials for the treatment of glaucoma.
In late February, NicOx SA (Paris: COX.PA) provided a corporate update which included a report on its US FDA review for an IOP (intraocular pressure) lowering singe-agent eye drop for patients with open-angle glaucoma
Santen Pharmaceuticals Co. Ltd. (Tokyo:4536.T; OTC: SNPHY) is focused on corneal disorders that lack effective treatment options and on glaucoma and retinal disorders that are increasing in prevalence due to the aging of society.
Novartis AG (NYSE:NVS) subsidiary Alcon, the global leader in eye care and a division of Novartis released news in February of 2016 announcing that it had entered into an agreement to acquire Transcend Medical, Inc., a privately-held, US-based company focused on developing minimally-invasive surgical devices to treat glaucoma.
Pfizer Inc’s (NYSE:PFE) Ophthalmology Unit indicates that it is interested in “establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers” in a number of ophthalmological areas including glaucoma.
Acadia Pharmaceuticals Inc.’s (NasdaqGS:ACAD) Muscarinic Program have discovered small-molecule product candidates for the treatment of glaucoma. Using a proprietary discovery platform, they identified a subtype of the muscarinic receptors that controls intraocular pressure and discovered lead compounds that selectively activate this target.
The Market Outlook:
The global glaucoma surgical devices market is expected to reach USD 3.11 billion by 2020, growing at a CAGR of close to 41%, according to Technavio’s latest report.
TechNavio's analysts forecast the Global Glaucoma Therapeutics market will grow at a CAGR of 2.53 percent over the period 2013-2018.
TechNavio's analysts forecast the Global Glaucoma Devices market to grow at a CAGR of 20.72 percent over the period 2013-2018.
About Q BioMed Inc. (OTCQB:QBIO):
Q BioMed Inc. ("Q") is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.
About Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI):
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma and ocular hypertension. It is expected that the NDA filing for Rhopressa™ (netarsudil ophthalmic solution) 0.02% will take place in the third quarter of 2016. The second product candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa™ and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a Roclatan™ NDA filing is expected to take place in the second half of 2017. In addition, Aerie is further building its pipeline, including through research collaborations with GrayBug, Inc. and Ramot at Tel Aviv University. http://www.aeriepharma.com/
About Glaukos (NYSE:GKOS):
Glaukos is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent® its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. http://www.glaukos.com/
About Inotek Pharmaceuticals Corp. (NasdaqGM:ITEK):
Inotek is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company's lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development Trabodenoson was developed in Inotek's laboratories and is designed to restore the eye's natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. http://www.inotekpharma.com/
About NicOx SA (Paris: COX.PA):
NicOx is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, Nicox is building a diversified portfolio of ophthalmic products that can help people enhance their sight. Nicox's advanced pipeline features latanoprostene bunod for the lowering of intra-ocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, and for which a New Drug Application (NDA) was submitted to the FDA by the Company's licensee Valeant. The Company's pipeline also features AC-170, a pre-NDA candidate for the treatment of ocular itching associated with allergic conjunctivitis, as well as two pre-MAA candidates in Europe: AzaSite® for bacterial conjunctivitis and BromSite(TM) for pain and inflammation after cataract surgery. Beyond these late-stage candidates, Nicox is developing a pipeline of next generation ophthalmology-focused candidates which utilize its proprietary nitric oxide (NO)-donating research platform. The Group has operations in Europe and the United States.
About Investorideas.com - Big Ideas for Global Investors
InvestorIdeas.com - digital media global news source, PR and social media in leading sectors.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for free news alerts at Investorideas.com
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: QBIO has retained investorideas.com for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800 665 0411